| Identification | Back Directory | [Name]
1H-Pyrazolo[3,4-d]pyrimidine-1-ethanol, 4-amino-3-[6-(cyclopropyloxy)-2-naphthalenyl]-α,α-dimethyl- | [CAS]
1951431-34-7 | [Synonyms]
1H-Pyrazolo[3,4-d]pyrimidine-1-ethanol, 4-amino-3-[6-(cyclopropyloxy)-2-naphthalenyl]-α,α-dimethyl- | [Molecular Formula]
C22H23N5O2 | [MOL File]
1951431-34-7.mol | [Molecular Weight]
389.45 |
| Chemical Properties | Back Directory | [Boiling point ]
651.7±55.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.27±0.29(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research[1]. | [in vivo]
BKIDC-1553 (20 mg/kg, p.o.,3 times weekly for 4 weeks) decreases tumor growth after 5 weeks in LuCaP 35 human PCa patient-derived xenograft mice [1].
| [References]
[1] Uo T, et al. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355. DOI:10.1101/2023.07.01.547355 |
|
|